Drugs / Trivalent virosomal influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02148328 | May → Oct 2014 | influenza | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent virosomal influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02148328 ↗ |
| Modality | Vaccine | “Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.” NCT02148328 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02148328 ↗ |